Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.46 |
| ▸ | MPC2 | O95563 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733582 | 1.00 | PPARG (0.49) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14733581 | 1.00 | PPARG (0.49) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213622 | 0.95 | PPARG (0.50) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213624 | 0.95 | PPARG (0.50) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213735 | 0.95 | PPARG (0.50) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213744 | 0.91 | PPARG (0.48) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213742 | 0.91 | PPARG (0.48) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213743 | 0.91 | PPARG (0.48) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213770 | 0.91 | FFAR1 (0.40) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213626 | 0.91 | FFAR1 (0.40) | PPARGFFAR1MPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885FFAR1 75/4885MPC2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.